12:00 AM
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Apremilast: Phase II data

The double-blind, international Phase II RA-002 trial in about 210 RA patients who had an inadequate response to methotrexate showed that twice-daily oral apremilast as an add-on therapy missed the primary endpoint of improving the proportion of patients achieving ACR20 response at week 16 vs. placebo. Details were...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >